Results for this period
First quarter1 April 2026 to 30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Revenue increased due to the recognition of final milestone revenue under a licensing agreement with an overseas pharmaceutical company. The Company reported an operating loss as it continued its research and development and business development activities.
Disclosure of material events and other matters. Although the recognition of an operating loss constitutes an event or situation that raises significant doubt about the going-concern assumption, the Company has determined, based on its funding plan and other considerations, that no material uncertainty exists.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥215 million (YoY +766.7%) |
| Operating profit | ¥-170 million |
| Ordinary income | ¥-133 million |
| Profit attributable to owners of the parent | ¥-134 million |
| Net income per share | -¥5.20 |
| Equity ratio | End of the current fiscal period 55.6 / End of previous period 65.5 |
| Total assets | ¥1,312 million |
| Net assets | ¥733 million |
| Full-year earnings forecast | Net Sales 1,100～1,500 / Operating profit 5～50 / Ordinary income 45～90 / Net income 45～90 |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Depreciation and amortization | ¥2,975 thousand |
| Disclosure regarding the going concern assumption | Disclosure of material events and other matters. Although the recognition of an operating loss constitutes an event or situation that raises significant doubt about the going-concern assumption, the Company has determined, based on its funding plan and other considerations, that no material uncertainty exists. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Added 1 company: 株式会社メディプロデュース (made a consolidated subsidiary effective 1 July 2026); removed 0 companies |
| Material subsequent events | All shares of 株式会社メディプロデュース were acquired and the company was made a subsidiary effective 1 July 2026. The acquisition cost was ¥150 million, and the voting rights acquired totaled 100%. The Company plans to prepare consolidated financial statements from the second quarter of the fiscal year. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 25,794,300 shares |
| Treasury Shares at Period-End | 0 shares |
| Factors Behind Changes in Business Performance | Revenue increased due to the recognition of final milestone revenue under a licensing agreement with an overseas pharmaceutical company. The Company reported an operating loss as it continued its research and development and business development activities. |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased due to the recognition of final milestone revenue under a licensing agreement with an overseas pharmaceutical company. However, the Company reported an operating loss as it continued its research and development and business development activities.